نتایج جستجو برای: expanded disability status scale edss

تعداد نتایج: 1070294  

2010
C Ford AD Goodman K Johnson N Kachuck JW Lindsey R Lisak C Luzzio L Myers H Panitch J Preiningerova A Pruitt J Rose H Rus J Wolinsky

The ongoing US Glatiramer Acetate (GA) Trial is the longest evaluation of continuous immunomodulatory therapy in relapsing-remitting multiple sclerosis (RRMS). The objective of this study was to evaluate up to 15 years of GA as a sole disease-modifying therapy. Two hundred and thirty-two patients received at least one GA dose since study initiation in 1991 (mITT cohort), and 100 (43%, Ongoing c...

Journal: :Journal of neurology, neurosurgery, and psychiatry 2017
Nathaniel Lizak Alessandra Lugaresi Raed Alroughani Jeannette Lechner-Scott Mark Slee Eva Havrdova Dana Horakova Maria Trojano Guillermo Izquierdo Pierre Duquette Marc Girard Alexandre Prat Pierre Grammond Raymond Hupperts Francois Grand'Maison Patrizia Sola Eugenio Pucci Roberto Bergamaschi Celia Oreja-Guevara Vincent Van Pesch Cristina Ramo Daniele Spitaleri Gerardo Iuliano Cavit Boz Franco Granella Javier Olascoaga Freek Verheul Csilla Rozsa Edgardo Cristiano Shlomo Flechter Suzanne Hodgkinson Maria Pia Amato Norma Deri Vilija Jokubaitis Tim Spelman Helmut Butzkueven Tomas Kalincik

OBJECTIVE To evaluate variability and predictability of disability trajectories in moderately advanced and advanced multiple sclerosis (MS), and their modifiability with immunomodulatory therapy. METHODS The epochs between Expanded Disability Status Scale (EDSS) steps 3-6, 4-6 and 6-6.5 were analysed. Patients with relapse-onset MS and having reached 6-month confirmed baseline EDSS step (3/4/...

2011
Bartolome Bejarano Mariangela Bianco Dolores Gonzalez-Moron Jorge Sepulcre Joaquin Goñi Juan Arcocha Oscar Soto Ubaldo Del Carro Giancarlo Comi Letizia Leocani Pablo Villoslada

BACKGROUND The aim of this study was to assess the diagnostic accuracy (sensitivity and specificity) of clinical, imaging and motor evoked potentials (MEP) for predicting the short-term prognosis of multiple sclerosis (MS). METHODS We obtained clinical data, MRI and MEP from a prospective cohort of 51 patients and 20 matched controls followed for two years. Clinical end-points recorded were: ...

2014
Murray G. Brown Mark Asbridge Vern Hicks Sarah Kirby Thomas J. Murray Pantelis Andreou Dong Lin Antony Bayer

INTRODUCTION Multiple sclerosis (MS) is a chronic disease of the central nervous system. Estimates of MS natural history (NH) disability progression speed from clinical observations vary worldwide. This may reflect, in part, variance in censoring-bias) (missing observations) and assumptions about when irreversible disability progression events occurred. We test whether estimates of progression ...

2016
Fawad Yousuf Gloria Kim Shahamat Tauhid Bonnie I. Glanz Renxin Chu Subhash Tummala Brian C. Healy Rohit Bakshi

OBJECTIVE To test a new version of the Magnetic Resonance Disease Severity Scale (v.3 = MRDSS3) for multiple sclerosis (MS), incorporating cortical gray matter lesions (CLs) from 3T magnetic resonance imaging (MRI). BACKGROUND MRDSS1 was a cerebral MRI-defined composite scale of MS disease severity combining T2 lesion volume (T2LV), the ratio of T1 to T2LV (T1/T2), and whole brain atrophy [br...

2001
M Wilson P S Morgan X Lin B P Turner L D Blumhardt

Objectives—To investigate the relations between quantitative diVusion coeYcient MRI histograms, clinical variables, and cerebral atrophy. Methods—Twenty two patients with clinically definite multiple sclerosis and 11 healthy volunteers were studied. Histograms of apparent diVusion coeYcient (ADC) from a volume of interest that included multiple slices encompassing the lateral ventricles were pr...

2016
Seyed Massood Nabavi S. M. Nabavi

Objective: To investigate the relationship between depression, fatigue, disability and cognitive skills of patients with multiple sclerosis in a cohort of patients with multiple sclerosis in a single center in Tehran, Iran. Methods: One hundred and forty-seven patients with multiple sclerosis with mean age of 33 years, mean disease duration of 20.20 months, mean EDSS of 2.13, and F to M ratio o...

2014
Arnaud Kwiatkowski Jean-Pierre Marissal Madani Pouyfaucon Patrick Vermersch Patrick Hautecoeur Benoît Dervaux

BACKGROUND Economic costs related to treatment of multiple sclerosis (MS) must be justified by health state, quality of life (QOL) and social participation improvement. This study aims to describe correlations between social participation, economic costs, utility and MS-specific QOL in a sample of patients with MS (pwMS). METHODS We interviewed 42 pwMS receiving natalizumab and collected clin...

Journal: :Multiple sclerosis 2004
M J Tullman R J Oshinsky F D Lublin G R Cutter

OBJECTIVE Patients with progressive relapsing (PR) multiple sclerosis (MS) may accrue disability by incomplete recovery from acute exacerbations and by ongoing deterioration. In primary progressive (PP) MS, disability accumulates solely by continuous decline. Because it is the least common form of MS, there is scant information regarding the clinical characteristics of PRMS, but relapses are re...

2015
Masoud Nikanfar Ali Akbar Taheri-Aghdam Maria Yazdani Sheida Shaafi Nooshin Masoudian Hossein Akbari Parisa Youhanaee Hamzeh Abbaszadeh

BACKGROUND It seems that serum vitamin D levels are one of the potential environmental factors affecting the severity of multiple sclerosis (MS). In this study, we aim to evaluate vitamin D levels in MS patients and healthy subjects and assess the relationship between vitamin D level and disability. METHODS In this case-control study, 168 rapid relapsing MS patients and 168 matched healthy co...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید